Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersHematology & Oncology Physician in Boston, MA
NPI: 1306041975Primary Practice Location
MASSACHUSETTS GENERAL HOSPITAL
55 Fruit St, Boston, MA
Primary Employer
Massachusetts General Physicians Organization Inc
massgeneral.org
HQ Phone
Get M.D. Dejan's Phone NumberMobile
Get M.D. Dejan's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardMA State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 72 | 334 |
| 2 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 16 | 41 |
| 3 | 99223Initial hospital inpatient care, typically 70 minutes per day | 11 | 11 |
PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer.
Authors: Aditya Bardia, Leif Ellisen
Publication Date: 2018-07-23
Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancer.
Authors: Aditya Bardia, Leif Ellisen, Steven Isakoff, Jennifer Aparicio, Jeffrey Peppercorn, Seth Wander, Irene Kuter, Laura Spring
Journal: Ther Adv Med Oncol
Publication Date: 2022-08-22
Authors: David Barch, James Cleary, Geoffrey Shapiro, Anthony Tolcher, Christopher Ocampo
Journal: Invest New Drugs
Publication Date: 2020-03-18
Lead Sponsor: Eli Lilly and Company
Intervention / Treatment: DRUG: Abemaciclib, DRUG: Fulvestrant, DRUG: Paclitaxel, DRUG: Imlunestrant, DRUG: LOXO-783, DRUG: Anastrozole, Exemestane, or Letrozole
Lead Sponsor: Cyteir Therapeutics, Inc.
Intervention / Treatment: DRUG: CYT-0851, DRUG: CYT-0851 in combination with gemcitabine, DRUG: CYT-0851 in combination with capecitabine, DRUG: CYT-0851 in combination with rituximab and bendamustine
Lead Sponsor: Vanderbilt-Ingram Cancer Center
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: laboratory biomarker analysis, DRUG: letrozole, DRUG: PI3K inhibitor BYL719, OTHER: pharmacological studies
